SLNO Stock Summary and Trading Ideas (Soleno Therapeutics | NASDAQ:SLNO)

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Soleno Therapeutics trades on the NASDAQ stock market under the symbol SLNO.

As of January 6, 2025, SLNO stock price declined to $45.90 with 266,389 million shares trading.

SLNO has a beta of 1.24, meaning it tends to be more sensitive to market movements. SLNO has a correlation of 0.10 to the broad based SPY ETF.

SLNO has a market cap of $1.98 billion. This is considered a Small Cap stock.

In the last 3 years, SLNO traded as high as $60.92 and as low as $.85.

The top ETF exchange traded funds that SLNO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

SLNO has underperformed the market in the last year with a return of +23.6%, while the SPY ETF gained +28.7%. In the last 3 month period, SLNO fell short of the market, returning -7.5%, while SPY returned +4.2%. However, in the most recent 2 weeks SLNO has outperformed the stock market by returning +2.1%, while SPY returned +0.1%.

SLNO support price is $45.09 and resistance is $47.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLNO shares will trade within this expected range on the day.